Ballicules.com

Oxybutynin ER

DITROPAN XL

What it isOxybutynin extended-release (DITROPAN XL, 1998) antagonizes muscarinic and H1 receptors; overactive bladder.

Why this oneIts apparent half-life ~13 h (vs ~2 h IR) smooths exposure and reduces dry mouth versus immediate release.

What limits itDry mouth, constipation, urinary retention, and cognitive impairment give it the heaviest anticholinergic burden among bladder drugs.

FDA-approved for

FDA label

FDA dosingPopulationStartTargetMax
Overactive bladder (urge urinary incontinence, urgency, frequency)Adults5 or 10 mg PO once daily30 mg/day
Detrusor overactivity associated with a neurological condition (e.g., spina bifida)Peds ≥6 yr5 mg PO once daily20 mg/day

Titration Adjust in 5 mg increments, generally at ~weekly intervals

Renal Undefined

Hepatic Undefined

Instructions

Contraindications

Cautions

Adverse reactions

Pregnancy No adequate data on use in pregnant women

Lactation No data on presence in human milk or effects on the breastfed infant

NO BOXED WARNINGS

Principal riskAnticholinergic burden, worst of the bladder agents

Classes and tags

Clinical profile

Direct muscarinic antagonism4 / 4

Mechanism of action: Oxybutynin ER ballicule

Oxybutynin ER ballicule: receptor binding, kinetics and half-life diagram

Open Oxybutynin ER in the interactive console ↗

Memory aids: mascots and interaction avatars

Oxybutynin ER DITROPAN mascot mnemonic cartoon
“Ox’s booty in a (ditro)pan”
“Mad as a hatter” → BBB-crossing anticholinergic
Oxybutynin ER CYP3A4 substrate avatar
CYP3A4 substrate

Open Oxybutynin ER in the interactive console ↗